Advertisement
Organisation › Details
Vedere Bio II Inc. (new, founded 10/20)
Vedere Bio II, which will be referred to as Vedere going forward, is a privately held, emerging biopharmaceutical company leveraging an ocular gene therapy toolbox to develop a pipeline of vision restoration and vision preservation therapies. Comprised of a diverse team of pioneering scientists, Vedere Bio II is discovering and developing next generation ocular gene therapies to make vision restoration a reality in areas of high global unmet medical need. The company is headquartered in Cambridge, MA and is funded by Atlas Venture, Mission BioCapital and Foundation Fighting Blindness (RD Fund). *
Start | 2020-10-29 established (approx) | |
Predecessor | Vedere Bio Inc. (old, sold to Novartis 9/20) | |
Industry | gene therapy eye disease | |
Region | Cambridge, MA | |
Country | United States (USA) | |
Street | 400 Technology Square 10th Floor | |
City | 02139 Cambridge, MA | |
Tel | +1-857-201-2700 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Vedere Bio, Inc.. (10/29/20). "Press Release: Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company". Cambridge, MA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Vedere Bio II Inc. (new, founded 10/20)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top